IP Library Granted Patent US 8,772,461
Granted Patent B2
US 8,772,461 · App. 12/937,454 · Granted Jul 8, 2014

Two-stage ultrafiltration/diafiltration

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,772,461
App. No.
12/937,454
Granted
Jul 8, 2014
Kind
B2
Abstract

The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a (two-stage ultrafiltration/diafiltration approach.

Claims (22)

1. A method for concentrating a plasma protein of a solution comprising the protein, the method comprising:

a) ultrafiltering the solution using a first membrane to form a first retentate solution comprising the protein at a first concentration, wherein the first membrane has a molecular weight cutoff sufficient to retain at least a portion of the protein present in the solution;

b) diafiltering the first retentate solution with an aqueous solution using the first membrane to form a second retentate solution comprising the protein at about the first concentration;

c) formulating the second retentate solution comprising the diafiltered protein with glycine and adjusting the pH to form a formulated second retentate solution; and

d) ultrafiltering the formulated second retentate solution of step c using a second membrane to form a final retentate solution comprising the protein at a second concentration, wherein the second membrane has a molecular weight cutoff of about twice the molecular weight cutoff of the first membrane, wherein the second concentration is greater than the first concentration.

2. The method of claim 1 , wherein the protein is IgG.

3. The method of claim 1 , wherein the first membrane is a polyethersulfone C-screen membrane having a molecular weight cutoff of 50 kDa.

4. The method of claim 1 , wherein the first concentration is about 5% protein (w/v).

5. The method of claim 1 , wherein the aqueous solution is a water.

6. The method of claim 1 , wherein the second membrane is a hollow fiber membrane.

7. The method of claim 1 , wherein the second membrane has a molecular weight cutoff of 100 kDa.

8. The method of claim 1 , wherein the second concentration is at least about 19% protein (w/v).

9. The method of claim 1 , wherein the first membrane has a molecular weight cutoff sufficient to retain at least 90% of the protein present in the solution.

10. The method of claim 4 , wherein the first concentration is about 5%, wherein, in step c), the about 5% diafiltered protein is formulated to about 0.16 to about 0.30 M glycine and the pH is adjusted to about 4.3.

11. A method for concentrating a protein of a solution comprising the protein, the method comprising:

a) ultrafiltering the solution using a first membrane to form a first retentate solution comprising the protein at a first concentration of about 5%, wherein the first membrane has a molecular weight cutoff sufficient to retain at least about 90% of the protein;

b) diafiltering the first retentate solution using the first membrane with water to form a second retentate solution comprising the protein at about the first concentration;

c) formulating the about 5% diafiltered protein of step b) to about 0.16 to about 0.30 M glycine, wherein the formulating further comprises adjusting pH to about 4.3; and

d) ultrafiltering the second retentate solution using a second membrane to form a final retentate solution comprising the protein at a second concentration of about 19 to about 21%, wherein the second membrane has a molecular weight cutoff of about twice the molecular weight cutoff of the first membrane, wherein the second concentration is greater than the first concentration.

12. The method of claim 11 , wherein the protein is IgG.

13. The method of claim 12 , wherein the first membrane has a molecular weight cutoff of about 25 kDa to about 75 kDa.

14. The method of claim 13 , wherein the first membrane has a molecular weight cutoff of about 50 kDa, wherein the second membrane has a molecular weight cutoff of about 100 kDa.

Assignments (31)
RELEASE OF SECURITY INTEREST IN PATENTS, RECORDED ON DECEMBER 10, 2021 AT REEL 058480 FRAME 0221 Recorded May 21, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (FORMERLY KNOWN AS GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (FORMERLY KNOWN AS GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS USA, LLC; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 075614/0936 →
RELEASE OF SECURITY INTEREST Recorded Apr 15, 2026
From: EUROPEAN INVESTMENT BANK
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (F/K/A GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (F/K/A GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 075416/0698 →
RELEASE OF SECURITY INTEREST Recorded Apr 15, 2026
From: EUROPEAN INVESTMENT BANK
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (F/K/A GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (F/K/A GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 075416/0718 →
RELEASE OF SECURITY INTEREST Recorded Apr 15, 2026
From: EUROPEAN INVESTMENT BANK
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (F/K/A GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (F/K/A GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 075416/0633 →
RELEASE OF SECURITY INTEREST Recorded Apr 15, 2026
From: THE BANK OF NEW YORK MELLON, LONDON BRANCH
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (F/K/A GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (F/K/A GRIFOLS BIOLOGICALS, INC.); GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; BIOMAT USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 075329/0824 →
SECURITY INTEREST Recorded May 14, 2024
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
To: THE BANK OF NEW YORK MELLON, LONDON BRANCH
Reel/Frame 067409/0127 →
PARTIAL RELEASE OF SECURITY INTEREST Recorded Dec 10, 2021
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: BIOMAT USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 058480/0221 →
PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME NO. 51021/0593 Recorded Dec 7, 2021
From: EUROPEAN INVESTMENT BANK
To: BIOMAT USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 058350/0980 →
PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME NO. 51024/0317 Recorded Dec 7, 2021
From: EUROPEAN INVESTMENT BANK
To: BIOMAT USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 058518/0524 →
PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME NO. 51024/0453 Recorded Dec 7, 2021
From: EUROPEAN INVESTMENT BANK
To: BIOMAT USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 058351/0064 →
PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME NO. 51047/0139 Recorded Dec 1, 2021
From: THE BANK OF NEW YORK MELLON, LONDON BRANCH
To: BIOMAT USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 058292/0564 →
SECURITY INTEREST Recorded Nov 18, 2019
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
To: THE BANK OF NEW YORK MELLON, LONDON BRANCH, AS NOTES COLLATERAL AGENT
Reel/Frame 051047/0139 →
SECURITY INTEREST Recorded Nov 18, 2019
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 051047/0123 →
RELEASE OF SECURITY INTEREST Recorded Nov 18, 2019
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (FORMERLY KNOWN AS GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (FORMERLY KNOWN AS GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
Reel/Frame 051047/0153 →
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2019
From: EUROPEAN INVESTMENT BANK
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (FORMERLY KNOWN AS GRIFOLS THERAPEUTICS, INC.; GRIFOLS BIOLOGICALS LLC (FORMERLY KNOWN AS GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
Reel/Frame 051064/0021 →
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2019
From: EUROPEAN INVESTMENT BANK
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (FORMERLY KNOWN AS GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (FORMERLY KNOWN AS GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.
Reel/Frame 051024/0722 →
SECURITY INTEREST Recorded Nov 15, 2019
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
To: EUROPEAN INVESTMENT BANK
Reel/Frame 051024/0453 →
SECURITY INTEREST Recorded Nov 15, 2019
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
To: EUROPEAN INVESTMENT BANK
Reel/Frame 051024/0317 →
SECURITY INTEREST Recorded Nov 15, 2019
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
To: EUROPEAN INVESTMENT BANK
Reel/Frame 051021/0593 →
SECURITY INTEREST Recorded Sep 7, 2018
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
To: EUROPEAN INVESTMENT BANK, AS LENDER
Reel/Frame 047438/0836 →
CHANGE OF ADDRESS Recorded Jun 1, 2018
From: GRIFOLS THERAPEUTICS LLC
To: GRIFOLS THERAPEUTICS LLC
Reel/Frame 046286/0824 →
CHANGE OF NAME Recorded Jan 5, 2018
From: GRIFOLS THERAPEUTICS INC.
To: GRIFOLS THERAPEUTICS LLC
Reel/Frame 045008/0573 →
SECURITY INTEREST Recorded Dec 5, 2017
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS BIOLOGICALS INC.; BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
To: EUROPEAN INVESTMENT BANK, AS LENDER
Reel/Frame 044697/0725 →
SECURITY INTEREST Recorded Dec 5, 2017
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS BIOLOGICALS INC.; BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.
To: EUROPEAN INVESTMENT BANK, AS LENDER
Reel/Frame 044696/0846 →
SECURITY INTEREST Recorded Feb 7, 2017
From: GRIFOLS SHARED SERVICES NORTH AMERICA INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS BIOLOGICALS INC.; BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 041651/0487 →
RELEASE OF SECURITY INTEREST Recorded Feb 6, 2017
From: DEUTSCHE BANK AG NEW YORK BRANK
To: GRIFOLS THERAPEUTICS INC.; GRIFOLS SHARED SERVICES NORTH AMERICA INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.
Reel/Frame 041638/0527 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 26390/0193 Recorded Jan 25, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: GRIFOLS, S.A.; GRIFOLS INC.; TALECRIS BIOTHERAPEUTICS, INC.
Reel/Frame 041494/0017 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2014
From: GONZALEZ, MARTIN; WOOD, WOODY D.; EARP, FRED H.
To: TALECRIS BIOTHERAPEUTICS, INC.
Reel/Frame 032994/0625 →
SECURITY AGREEMENT Recorded Feb 27, 2014
From: GRIFOLS INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS-CHIRON DIAGNOSTICS CORP.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032367/0001 →
CHANGE OF NAME Recorded Jun 18, 2013
From: TALECRIS BIOTHERAPEUTICS, INC.
To: GRIFOLS THERAPEUTICS INC.
Reel/Frame 030650/0819 →
SECURITY AGREEMENT Recorded Jun 3, 2011
From: GRIFOLS, S.A.; GRIFOLS INC.; TALECRIS BIOTHERAPEUTICS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 026390/0193 →